Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics


Enanta Pharmaceuticals, Inc. (ENTA): $49.32

-1.26 (-2.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

ENTA Stock Summary

  • Of note is the ratio of Enanta Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 8.04% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, Enanta Pharmaceuticals Inc is reporting a growth rate of -419.8%; that's higher than only 4.44% of US stocks.
  • Revenue growth over the past 12 months for Enanta Pharmaceuticals Inc comes in at -45.9%, a number that bests just 6.51% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Enanta Pharmaceuticals Inc are ANAB, CARA, MORF, RAPT, and MGNX.
  • ENTA's SEC filings can be seen here. And to visit Enanta Pharmaceuticals Inc's official web site, go to www.enanta.com.

ENTA Stock Price Chart Interactive Chart >

Price chart for ENTA

ENTA Price/Volume Stats

Current price $49.32 52-week high $58.59
Prev. close $50.58 52-week low $38.40
Day low $47.95 Volume 279,000
Day high $51.06 Avg. volume 153,537
50-day MA $47.81 Dividend yield N/A
200-day MA $47.76 Market Cap 994.88M

Enanta Pharmaceuticals, Inc. (ENTA) Company Bio


Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.


ENTA Latest News Stream


Event/Time News Detail
Loading, please wait...

ENTA Latest Social Stream


Loading social stream, please wait...

View Full ENTA Social Stream

Latest ENTA News From Around the Web

Below are the latest news stories about Enanta Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

Business Wire | February 18, 2021

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2021 Results - Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2021 Earnings Conference Call February 08, 2021 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President & Chief Executive Officer Paul Mellett - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Securities Rachel Vatnsdal - Piper Sandler Brian...

SA Transcripts on Seeking Alpha | February 9, 2021

Enanta Pharma EPS beats by $0.39, beats on revenue

Enanta Pharma (ENTA): FQ1 GAAP EPS of -$0.41 beats by $0.39.Revenue of $31.74M (-39.6% Y/Y) beats by $4.01M.Royalty Revenue for the quarter was $31.7M.Cash and marketable securities totaled $404.7M at Dec. 31, 2020.Press Release...

Seeking Alpha | February 8, 2021

Enanta Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 8, 2021 / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on February 8, 2021 at 4:30 PM Eastern Time.

Yahoo Finance | February 8, 2021

Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals By Investing.com

Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals

Investing.com | February 8, 2021

Read More 'ENTA' Stories Here

ENTA Price Returns

1-mo 2.62%
3-mo 19.71%
6-mo -1.00%
1-year -3.07%
3-year -36.71%
5-year 65.06%
YTD 17.15%
2020 -31.85%
2019 -12.78%
2018 20.71%
2017 75.16%
2016 1.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9336 seconds.